RxSight, Inc. appears in FDA device records as the applicant for a single premarket approval family, P160055, covering the Light Adjustable Lens and the Light Delivery Device used with it. The original approval carries a 2017 decision date, and later supplements document changes to device software, lens identification methods and supplier arrangements. The records describe the system as a posterior chamber intraocular lens paired with an ultraviolet light source device, classified in the ophthalmic specialty. The filing address listed by FDA is in Aliso Viejo, California; that address is a filing detail, not a verified headquarters. [1][4][7]
The approved system and its components
FDA's Summary of Safety and Effectiveness Data names the device generic descriptions as a posterior chamber intraocular lens and an ultraviolet light source device, with trade names Light Adjustable Lens (LAL) and Light Delivery Device (LDD). The same document lists the applicant as RxSight, Inc. of 100 Columbia, Aliso Viejo, CA 92656, and records the PMA number as P160055 with an FDA notice of approval dated 11/22/2017. The openFDA record for the original approval matches that decision date and lists product code PZK, regulation number 886.3600 and device class 3. [4][7]
The approved indication described in the FDA record concerns reduction of residual astigmatism to improve uncorrected visual acuity after removal of the cataractous natural lens by phacoemulsification and implantation of the intraocular lens in the capsular bag, and reduction of the likelihood of clinically significant residual spherical refractive errors. The record states the indication applies to adult patients with stated pre-existing conditions. The Light Delivery Device appears in later supplements as specific models, including Model 61002-006 and Model 61002-007 software. [3][4]
Recent supplement activity
Supplement S057, received 2026-08-07 and decided 2026-11-05 with an approval code, covers an Align Assist module modification that replaces a template-matching lens identification method with a locked machine learning-based lens identification algorithm. FDA classifies it as a real-time process supplement with the reason change design/components/specifications/material. The applicant is listed as Rxsight, Inc. [1]
Supplement S056, received 2026-06-08 and decided 2026-09-03 with an approval code, covers updates to Light Delivery Device Model 61002-006 and Model 61002-007 software, described as minor graphical user interface enhancements, improvements to internal manufacturing and service tools, software processing optimizations and resolution of identified bugs. Supplement S058, received 2026-09-22 and decided 2026-10-22 under a 30-day notice code, concerns changing the location of a supplier manufacturing site for a critical raw precursor material used in LAL and LAL+ devices. [2][3]
How the filing record is organized
The collected FDA records for this applicant total four linked premarket approval entries, all on the PMA pathway, with decision counts of three approvals and one 30-day notice. The smaller record sample of four entries shows the same split of three approvals and one 30-day notice. These counts describe the retrieved filings as of the snapshot date and are not measures of total company portfolio, sales or safety performance. [1][2][3][4]
A broader openFDA query combining several applicants returned 56 results in total; that figure applies to the combined query rather than to RxSight alone, and no per-applicant total is established here. One retrieved record, S032, documents approval of minor design modifications to an optical assembly inside Light Delivery Device Model 61002-007, received 2025-03-17 and decided 2025-06-11. No recall records appear in the retrieved sample. [8]




